Therapy for pelvic pain associated with endometriosis: overcoming unresolved issues
https://doi.org/10.33667/2078-5631-2020-26-38-44
Abstract
The review is devoted to the problem of choosing the optimal tactics for managing patients with endometriosis-associated pelvic pain in the context of ensuring the quality of life and maintaining fertility. Diagnosis of endometriosis by direct imaging has recently come under criticism due to the inevitable delay in making a definitive diagnosis. Surgery should not be an option for all patients with suspected endometriosis, and empirical hormone therapy is relevant, as is the task of prescribing long-term therapy to improve quality of life. Modern ideas about the pathogenesis of endometriosis, the origin of pelvic pain and the pharmacological properties of hormonal drugs, outlined in the article, make it possible to build a concept of long-term management of women with pelvic pain, precisely or presumably associated with endometriosis.
About the Author
I. V. Kuznetsova
Higher Medical School, Moscow Academical Clinic ‘ECO’
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014; 348: g1752. [PubMed: 24647161]
2. Cousins FL, O DF, Gargett CE. Endometrial stem/ progenitor cells and their role in the pathogenesis of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018; 50: 27–38. DOI: 10.1016/j.bpobgyn.2018.01.011.
3. Méar L, Herr M, Fauconnier A, Pineau C, Vialard F. Polymorphisms and endometriosis: a systematic review and meta-analyses. Hum Reprod Update. 2020; 26 (1): 73–102. DOI: 10.1093/humupd/dmz034.
4. Bruner-Tran KL, Resuehr D, Ding T, JA L, Osteen K. The Role of Endocrine Disruptors in the Epigenetics of Reproductive Disease and Dysfunction: Potential Relevance to Humans. Current Obstet Gynecol Rep. 2012; 1: 116–123.
5. Bruner-Tran KL, Mokshagundam S, Herington JL, Ding T, Osteen KG. Rodent Models of Experimental Endometriosis: Identifying Mechanisms of Disease and Therapeutic Targets. Curr Womens Health Rev. 2018; 14 (2): 173–188. DOI: 10.2174/1573404813666170921162041.
6. Herington JL, Bruner-Tran KL, Lucas JA, Osteen KG. Immune interactions in endometriosis. Expert Rev Clin Immunol. 2011; 7: 611–626.
7. Оразов М. Р., Духин А. О., Носенко Е. Н. Роль пролиферации и апоптоза при аденомиозе, сопровождающемся синдромом хронической тазовой боли. Доктор.Ру. 2016; 3 (120): 5–8.
8. Hu X, Zhou Y, Feng Q, Wang R, Su L, Long J, Wei B. Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2012; 164 (1): 1–9. DOI: 10.1016/j.ejogrb.2012.05.008.
9. Shao R, Cao S, Wang X, Feng Y, Billig H. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. Am J Transl Res 2014; 6 (2): 104–113.
10. Campbell L, Emmerson E, Williams H, Saville CR, Krust A, Chambon P, Mace KA, Hardman MJ. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. J Invest Dermatol. 2014; 134 (9): 2447–2457.
11. Heublein S, Vrekoussis T, Kuhn C, Friese K, Makrigiannakis A, Mayr D, Lenhard M, Jeschke U. Inducers of G-protein coupled estrogen receptor (GPER) in endometriosis: potential implications for macrophages and follicle maturation. J Reprod Immunol. 2013; 97 (1): 95–103.
12. Okamoto M, Suzuki T, Mizukami Y, Ikeda T. The membrane-type estrogen receptor G-protein-coupled estrogen receptor suppresses lipopolysaccharide-induced interleukin 6 via inhibition of nuclear factor-kappa B pathway in murine macrophage cells. Anim Sci J. 2017; 88 (11): 1870–1879.
13. Bulun SE, Cheng Y-H, Pavone ME, et al. 17β-Hydroxysteroid Dehydrogenase-2 Deficiency and Progesterone Resistance in Endometriosis. Semin Reprod Med. 2010; 28 (1): 44–50.
14. Szczepańska M, Wirstlein P, Skrzypczak J, Jagodziński PP. Expression of HOXA11 in the mid-luteal endometrium from women with endometriosis-associated infertility. Reprod Biol Endocrinol. 2012; 10 (1): 1.
15. Liang Y, Yao S. Potential role of estrogen in maintaining the imbalanced sympathetic and sensory innervation in endometriosis. Mol Cell Endocrinol. 2016; 424: 42–49. DOI: 10.1016/j.mce.2016.01.012.
16. Barcena DAM, Oldeweme J, Arnold J, Schneider A, Mechsner S. Remodeling of estrogen-dependent sympathetic nerve fibers seems to be disturbed in adenomyosis. Fertil Steril. 2013; 100 (3): 801–809.
17. Monica BM, Smith PG. Estrogen and female reproductive tract innervation: cellular and molecular mechanisms of autonomic neuroplasticity. Auton Neurosci. 2015; 187: 1–17.
18. Greaves E, Collins F, Esnal-Zufiaurre A, Giakoumelou S, Horne AW, Saunders PT. Estrogen receptor (ER) agonists differentially regulate neuroangiogenesis in peritoneal endometriosis via the repellent factor SLIT3. Endocrinology. 2014; 155 (10): 4015–4026.
19. Rowan MP, Berg KA, Roberts JL, Hargreaves KM, Clarke WP. Activation of estrogen receptor alpha enhances bradykinin signaling in peripheral sensory neurons of female rats. J Pharmacol Exp Ther. 2014; 349 (3): 526–532.
20. Altun I, Kurutas EB. G protein-coupled estrogen receptor levels after peripheral nerve injury in an experimental rat model. World Neurosurg. 2015; 84 (6): 1903–196.
21. Zhang X, Lu B, Huang X, Xu H, Zhou C, Lin J. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil Steril. 2010; 94 (2): 730–737. DOI: 10.1016/j.fertnstert.2009.03.026.
22. Miller EJ, Fraser IS. The importance of pelvic nerve fibers in endometriosis. Womens Health (Lond). 2015; 11 (5): 611–618.
23. Yan D, Liu X, Guo SW. Nerve fibers and endometriotic lesions: partners in crime in inflicting pains in women with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 14–24. DOI: 10.1016/j.ejogrb.2016.06.017.
24. McKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil Steril. 2012; 97 (2): 373–380. DOI: 10.1016/j.fertnstert.2011.11.011.
25. Wang G, Tokushige N, Fraser IS. Nerve fibers and menstrual cycle in peritoneal endometriosis. Fertil Steril. 2011; 95 (8): 2772–2274. DOI: 10.1016/j.fertnstert.2011.01.150.
26. Wei Y, Liang Y, Lin H, Dai Y, Yao S. Autonomic nervous system and inflammation interaction in endometriosis-associated pain. J Neuroinflammation. 2020; 17 (1): 80. DOI: 10.1186/s12974–020–01752–1.
27. Liang Y, Xie H, Wu J, Liu D, Yao S. Villainous role of estrogen in macrophage-nerve interaction in endometriosis. Reprod Biol Endocrinol. 2018 Dec 5; 16 (1): 122. DOI: 10.1186/s12958–018–0441-z.
28. Forster R, Sarginson A, Velichkova A, Hogg C, Dorning A, Horne AW, Saunders PTK, Greaves E. Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and nerve-sensitizing factor in pain associated with endometriosis. FASEB J. 2019 Oct; 33 (10): 11210–11222. DOI: 10.1096/fj.201900797R.
29. Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011; 96 (2): 366–373.
30. Hansen KE, Kesmodel US, Baldursson EB, Kold M, Forman A. Visceral syndrome in endometriosis patients. Eur J Obstet Gynecol Reprod Biol 2014; 179: 198–203.
31. Facchin F, Barbara G, Dridi D, et al. Mental health in women with endometriosis: searching for predictors of psychological distress. Hum Reprod 2017; 32 (9): 1855–1861.
32. Zarbo C, Brugnera A, Dessì V, et al. Cognitive and Personality Factors Implicated in Pain Experience in Women with Endometriosis: A Mixed Method Study. Clin J Pain 2019; 35 (12): 948–957.
33. Maggiore LRU, Bizzarri N, Scala C, Tafi E, Siesto G, Alessandri F, Ferrero S. Symptomatic endometriosis of the posterior cul-de-sac is associated with impaired sleep quality, excessive daytime sleepiness and insomnia: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 39–43.
34. Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centers. Hum Reprod 2012; 27: 1292–1299.
35. Kundu S, Wildgrube J, Schippert C, Hillemanns P, Brandes I. Supporting and Inhibiting Factors When Coping with Endometriosis from the Patients′ Perspective. Geburtshilfe Frauenheilkd. 2015; 75 (5): 462–469.
36. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013; 28 (6): 1552–1568.
37. Mowers EL, Lim CS, Skinner B, Mahnert N, Kamdar N, Morgan, DM, As-Sanie S. Prevalence of Endometriosis During Abdominal or Laparoscopic Hysterectomy for Chronic Pelvic Pain. Obstet Gynecol 2016; 127 (6): 1045–1053.
38. Streuli I, de Ziegler D, Gayet V, Santulli P, Bijaoui G, de Mouzon J, Chapron C. In women with endometriosis anti-Mullerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod. 2012; 27: 3294–3303.
39. Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29 (3): 400–412.
40. Durham JD, Machan L. Pelvic congestion syndrome. Semin Intervent Radiol. 2013; 30 (4): 372–380. DOI: 10.1055/s-0033–1359731.
41. Speer LM, Mushkbar S, Erbele T. Chronic Pelvic Pain in Women. Am Fam Physician. 2016; 93 (5): 380–387. PMID: 26926975.
42. Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier Consortium: Consensus on current management of endometriosis. Hum Reprod 2013; 28 (6): 1552–1568.
43. Hong IS, Klausen C, Cheung AP, Leung PC. Gonadotropin-releasing hormone-I or II interacts with IGF-I/ Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrin Metab 2012; 97 (2): 525–534.
44. Nigrinakis K, Bersinger NA, McKinnon B, et al. Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur J Obstet Gynecol Reprod Biol 2013; 170 (2): 550–554.
45. Muramatsu T. Structure and function of midkine as a basis of its pharmacological effects. Br J Pharmacol 2014; 171 (4): 814–826.
46. Huang F, Wang H, Zou Y, Liu Q, Cao J, Yin. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. Int J Clin Exp Pathol. 2013; 6 (11): 2487–2496.
47. Alshehre SM, Duffy S, Jones G, Ledger WL, Metwally M. A prospective, single-centre, single-arm, open label study of the longterm use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain. Reprod Biol Endocrinol. 2020; 18 (1): 28. DOI: 10.1186/s12958–020–00586-z.
48. Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health. 2011; 3: 175–184. DOI: 10.2147/IJWH.S5633.
49. Bedaiwy MA, Allaire C, Alfaraj S: Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017; 107 (3): 537–548.
50. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016; 65 (3): 183–192. DOI: 10.1007/s00011–015–0909–7.
51. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids. 2011; 76 (1–2): 60–7. DOI: 10.1016/j.steroids.2010.08.010.
52. Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil Steril. 2012; 97 (2): 477–482.
53. Mita S, Shimizu Y, Sato A, Notsu T, Imada K, Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. Fertil Steril. 2014; 101 (2): 595–601.
54. Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest. 2015; 38 (11): 1211–8. DOI: 10.1007/s40618–015–0383–7.
55. Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother. 2014; 15 (6): 767–773.
56. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015; 292 (3): 523–529. DOI: 10.1007/s00404–015–3681–6.
57. Тихонова Е. С. Медицинские и социальные аспекты генитального эндометриоза: Автореф. дис. … канд. мед. наук. М., 2013; 26 с.
58. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017; 211: 108–111. DOI: 10.1016/j.ejogrb.2017.02.015.
59. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015; 104 (4): 793–801. DOI: 10.1016/j.fertnstert.2015.08.026.
60. Bedaiwy M, Allaire C, Yong P, et al. Medical Management of Endometriosis in Patients with Chronic Pelvic Pain. Semin Reprod Med 2017; 35 (1): 38–53.
61. Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018; 5 (5): CD001019. DOI: 10.1002/14651858.CD001019.pub3.
62. Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 39(8): 923–931.
63. Schindler AE. Non-contraceptive benefits of hormonal contraception. Minerva Ginecol 2010; 62: 319–329.
64. Wiegratz I, Stahlberg S, Manthey T, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011; 84 (2): 133–143.
65. Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93: 2150–2161.
66. Dmitrovic R, Kunselman AR, Legro RS. Continuous Compared with Cuclic Oral Contraceptives for the Treatment of Primary Dysmenorrhea: A Randomized Controlled Trial. Obstet Gynecol 2012; 119 (6): 1143–1150.
67. Practice Committee of the American Society for Reproductive Medicine: Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101 (4): 927–935.
68. Ulrich U, Buchweitz O, Greb R, et al, for the German and Austrian Societies for Obstetrics and Gynecology. National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version – AWMF Registry No. 015–045. Geburtshilfe Frauenheilkd 2014; 74 (12): 1104–1118.
69. Royal College of Obstetricians and Gynecologists, Faculty of Sexual & Reproductive Health Care. Contraception for Women Aged over 40 years; 2010 www.fsrh.org/pages/clinical guidance.asp
70. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631–650.
71. Mueck AO, Seeger H, Ruan X. Oral contraception and risk of endometrial cancer. J Contracept 2011; 2: 127–136.
72. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an International Workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–122.
73. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis (review). Cochrane Library 2014; (3). www.thecochranelibrary.com.
74. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345: e4944. DOI.org/10.1136/bmj.e4944.
Review
For citations:
Kuznetsova I.V. Therapy for pelvic pain associated with endometriosis: overcoming unresolved issues. Medical alphabet. 2020;(26):38-44. (In Russ.) https://doi.org/10.33667/2078-5631-2020-26-38-44
Views:
178
Email this article 